Schizophrenia Research
Volume 117, Issue 1 , Pages 68-74 , March 2010

Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study

  • Marc De Hert

      Affiliations

    • University Psychiatric Center, Catholic University Leuven, Campus Kortenberg, Belgium
    • Corresponding Author InformationCorresponding author. UPC KUL Campus Kortenberg, Leuvensesteenweg 517, 3070 Kortenberg, Belgium.
    • ,
  • Christoph U. Correll

      Affiliations

    • The Zucker Hillside Hospital, Glen Oaks, New York, USA
    • Albert Einstein College of Medicine, Bronx, New York, USA
    • ,
  • Dan Cohen

      Affiliations

    • Department of Epidemiology, University Medical Centre Groningen, University of Groningen, Netherlands
    • Division Chronic Care, Noord-Holland-Noord, GGZ-NHN, Heerhugowaard, Netherlands

Received 10 September 2009 ,Revised 24 November 2009 ,Accepted 19 December 2009.

References 

  1. Basu D, Aggarwal M. Mortality in patients with schizophrenia. Lancet. 2009;374(9701):1591
  2. Beral V the Million Women Study collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet. 2003;362:419–427
  3. Beral V, Bull D, Reeves G Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365:1543–1551
  4. Cohen D, Correll CU. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors and screening need. J. Clin. Psychiatry. 2009;70:765–766
  5. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. 2009;35(2):443–457
  6. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–1773
  7. De Hert M, McKenzie K, Peuskens J. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophr. Res. 2001;47(2–3):127–134
  8. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr. Res. 2008;101(1-3):295–303
  9. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur. Psychiatry. 2009;24(6):412–424
  10. De Hert M, Peuskens J, van Winkel R. Mortality in patients with schizophrenia. Lancet. 2009;374(9701):1591
  11. Dervaux A, Laqueille X. Mortality in patients with schizophrenia. Lancet. 2009;374(9701):1592
  12. Eronen M, Repo E, Vartiainen H, Tiihonen J. Forensic psychiatric organization in Finland. Int. J. Law Psychiatry. 2000;23(5–6):541–546
  13. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens C, Lambert M, Leucht S, et al. Cormorbid somatic illnesses in patients with severe mental disorders: clinical, policy and research challenges. J. Clin. Psychiatry. 2008;69:514–519
  14. Haukka J, Tiihonen J, Härkänen T, Lönnqvist J. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol. Drug Saf. 2008;17(7):686–696
  15. Heilä H, Haukka J, Suvisaari J, Lönnqvist J. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol. Med. 2005;35(5):725–732
  16. Hill AB. The environment and disease; association or causation. Proc. Royal Soc. Med. 1965;8:295–330
  17. Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br. J. Psychiatry. 2006;188:122–127
  18. Korkeila J. Current trends in psychiatry care in Finland with special focus on private practice psychiatry and psychotherapy. Nord. J. Psychiatry. 2009;63(1):87–90
  19. Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry. 2007;68(6):899–907
  20. Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch. Gen. Psychiatry. 2009;66(7):713–720
  21. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia. Acta Psychiatr. Scand. 2007;116(5):317–333
  22. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry. 2003;60(1):82–91
  23. Munro J, O'Sullivan D, Anderws C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12.760 clozapine recipients in the UK and Ireland. Brit. J. Psych. 1999;175:576–580
  24. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch. Gen. Psychiatry. 2007;64(2):242–249
  25. Osby U. Cardiovascular outcome and schizophrenia in Sweden. Schizophr. Res. 2008;103(1–3):18
  26. Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ. 2000;321(7259):483–484
  27. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch. Gen. Psychiatry. 2005;62(3):247–253
  28. Pirkola S, Sohlman B, Heilä H, Wahlbeck K. Reductions in postdischarge suicide after deinstitutionalization and decentralization: a nationwide register study in Finland. Psychiatr. Serv. 2007;58(2):221–226
  29. Pirkola S, Sund R, Sailas E, Wahlbeck K. Community mental-health services and suicide rate in Finland: a nationwide small-area analysis. Lancet. 2009;373(9658):147–153
  30. Rantanen H, Koivisto AM, Salokangas RK, Helminen M, Oja H, Pirkola S, et al. Five-year mortality of Finnish schizophrenia patients in the era of deinstitutionalization. Soc. Psychiatry Psychiatr. Epidemiol. 2009;44(2):135–142
  31. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 2009;360(3):225–235
  32. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry. 2007;64(10):1123–1131
  33. Salokangas RKR, Honkonen T, Stengard E, Koivisto AM. Mortality in chronic schizophrenia during decreasing number of psychiatric beds in Finland. Schizophr. Res. 2002;54:265–275
  34. Sperling W, Biermann T. Mortality in patients with schizophrenia. Lancet. 2009;374(9701):1592
  35. STAKES, 2009. www.info.stakes.fi/mindful/EN/database/indicators.htm (accessed 28 07 2009).
  36. Taylor DM, Douglas-Hall P, Olofinjana B, Whiskey E, Thomas A. Reasons for discontinuing clozapine: matched, case–control comparison with risperidone long-acting injection. Br. J. Psychiatry. 2009;194(2):165–167
  37. Tidemalm D, Margda Waern M, Stefansson CG, Elofsson S, Runeson B. Excess mortality in persons with severe mental disorder in Sweden: a cohort study of 12,103 individuals with and without contact with psychiatric services. Clin. Pract. Epidemiol. Ment. Health. 2008;4:23
  38. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch. Gen. Psychiatry. 2006;63(12):1358–1367
  39. Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333:224–227
  40. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–627
  41. van der Mooren MJ, Kenemans P. The Million Women Study: a licence to kill other investigations?. Eur. J. Obstet. Gynecol. Reprod. Biol. 2004;113(1):3–5
  42. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br. J. Psychiatry. 1998;173:325–329
  43. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology. 1997;8(6):671–677
  44. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr. Res. 2009;113(1):1–11
  45. Whitehead M, Farmer R. The million women study. A critique. Endocrine. 2004;24(3):187–193

PII: S0920-9964(09)00620-3

doi: 10.1016/j.schres.2009.12.029

Schizophrenia Research
Volume 117, Issue 1 , Pages 68-74 , March 2010

Article Tools